Duodenal cancer is considered to be a small intestinal carcinoma in terms of
clinicopathology. In Japan, there are no established treatment guidelines based on sufficient …

Small bowel cancers account for 3% of all gastrointestinal malignancies and small bowel
adenocarcinomas represent a third of all small bowel cancers. Rarity of small bowel …

Objective This study was carried out to determine relative survival rates and trends in
outcomes in patients who underwent resection of periampullary adenocarcinomas (PACs) …

Background Duodenal adenocarcinoma (DA) is a rare tumor for which survival data per
treatment modality and disease stage are unclear. This systematic review and meta-analysis …

Background: Endoscopic submucosal resection (ESD) and endoscopic mucosal resection
(EMR) are well established as curable and safety procedures for treating superficial tumors …

BACKGROUND The role of adjuvant chemotherapy (AC) in the treatment of small bowel
adenocarcinoma is poorly defined. Previous analyses have been limited by small sample …

Duodenal adenocarcinoma is a rare but aggressive malignancy. Given its rarity, previous
studies have traditionally combined duodenal adenocarcinoma (DA) with either other …

Background and study aims: The clinical benefit of endoscopic submucosal dissection
(ESD) for superficial duodenal neoplasias has not yet been verified. The aims of this study …

Background Because duodenal adenocarcinoma (DA) is relatively rare, few studies have
investigated the impact of resection type on long-term outcomes. Methods The Surveillance …

Background Factors influencing long-term outcome after surgical resection for duodenal
adenocarcinoma are unclear. Methods A prospectively created database was reviewed for …